Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/27/2009

p>

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription laxative. The Company also recently received FDA approval for Caldolor(R), the first injectable treatment for pain and fever available in the United States, and is preparing for the commercial launch of that product. Cumberland is dedicated to providing innovative products which improve quality of care for patients.

For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information,
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Cumberland Pharmaceuticals Announces Appointments
3. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Deer Path of ... host a Valentine’s Day Happy Hour from 3 p.m. to 4 ... 12500 Regency Parkway in Huntley, Illinois, serves adults with physical disabilities ... event will include Valentine's Day treats, games and sweetheart-themed karaoke. , ...
(Date:1/22/2015)... PA (PRWEB) January 22, 2015 Woodloch Pines, ... Mountains, has been selected by TripAdvisor as the number one ... the 6th best in the world for their annual Travelers’ ... online travel community . The website is home to millions ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... given to nurse practitioners conducting outstanding research in ... ... Mission Pharmacal today,congratulated the winners of the National Association of Nurse,Practitioners ... Conference in Philadelphia, Pennsylvania. The,awards are given to the authors of ...
... CYNO ), a leading developer and manufacturer ... today announced that the company,will host its third-quarter ... 9:00 a.m. ET. On the call, President ... President and Chief Financial Officer Timothy Baker will,discuss ...
... They Are More Adventurous and Willing to ... They Were in Their 20s, - Boomers Can Stay On-the-Go with ... a recent study, sixty-,four percent of baby boomers claim they feel ... half (48 percent) say they are more,adventurous and willing to experiment ...
... Micromet, Inc.,(Nasdaq: MITI ), a biopharmaceutical ... products for the treatment of cancer,inflammatory and autoimmune ... an Investigational Medicinal Product Dossier (IMPD),for the conduct ... in patients with,acute lymphoblastic leukemia (ALL) in Germany. ...
... for Third Consecutive Quarter, DEERFIELD, Ill., Oct. 18 ... strong financial results for the period,ended September 30, 2007 ... Third quarter net income of $395 million increased ... quarter of 2006. Net earnings per,diluted share of $0.61 ...
... 18 While shopping is usually viewed as,a ... shopper in twenty, the,habit is a process addiction. ... than holiday buying and trying on new work ... that can spiral into financial and,emotional disaster. ...
Cached Medicine News:Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 2Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 3Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 4Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 5Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 6Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 7Health News:Cynosure to Announce Third-Quarter 2007 Financial Results on November 1 2Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 2Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 3Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 4Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Health News:Baxter Reports Strong Third Quarter Sales and Earnings 2Health News:Baxter Reports Strong Third Quarter Sales and Earnings 3Health News:Baxter Reports Strong Third Quarter Sales and Earnings 4Health News:Baxter Reports Strong Third Quarter Sales and Earnings 5Health News:Baxter Reports Strong Third Quarter Sales and Earnings 6Health News:Baxter Reports Strong Third Quarter Sales and Earnings 7Health News:Baxter Reports Strong Third Quarter Sales and Earnings 8Health News:Baxter Reports Strong Third Quarter Sales and Earnings 9Health News:Baxter Reports Strong Third Quarter Sales and Earnings 10Health News:Baxter Reports Strong Third Quarter Sales and Earnings 11Health News:Baxter Reports Strong Third Quarter Sales and Earnings 12Health News:Baxter Reports Strong Third Quarter Sales and Earnings 13Health News:Baxter Reports Strong Third Quarter Sales and Earnings 14Health News:Baxter Reports Strong Third Quarter Sales and Earnings 15Health News:Baxter Reports Strong Third Quarter Sales and Earnings 16Health News:Baxter Reports Strong Third Quarter Sales and Earnings 17Health News:Baxter Reports Strong Third Quarter Sales and Earnings 18Health News:Baxter Reports Strong Third Quarter Sales and Earnings 19Health News:Baxter Reports Strong Third Quarter Sales and Earnings 20Health News:Baxter Reports Strong Third Quarter Sales and Earnings 21Health News:Baxter Reports Strong Third Quarter Sales and Earnings 22
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
(Date:1/23/2015)... Inc., a leader in hand hygiene monitoring, today announced ... subsidiary of Ascendis Health Limited, in Johannesburg, ... of millions of patients around the world are affected ... patient to patient via the unwashed hands of healthcare ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... April 28 The biopharma mega-mergers that grabbed headlines last year ... are now in the critical post-integration period and the acquiring companies are ... too early for final verdicts, but clearly one M&A issue that continues ... , , , ...
... DAYTONA BEACH, Fla. and MT. LAUREL, N.J. , ... part of its "First Time Right" quality service initiative, MedQuist ... clinical documentation services, will begin offering BenchMark KB ... users, during Q210.  BenchMark KB, created by InterFix LLC, is ...
Cached Medicine Technology:Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 3MedQuist Launches BenchMark KB(R) Knowledge Base 2MedQuist Launches BenchMark KB(R) Knowledge Base 3MedQuist Launches BenchMark KB(R) Knowledge Base 4MedQuist Launches BenchMark KB(R) Knowledge Base 5
The Abbott Commander is an automated, high-throughput immunoassay testing system. The Commander System consists of the Flexible Pipetting Center, the Parallel Processing Center, and the Dynamic Incub...
... The GenoSensor System includes genomic ... software, and reagents. By utilizing ... (CGH) technology for multi-target assessment, ... analyze multiple genomic targets in ...
The ABI PRISM 3100 Genetic Analyzer, a multi-color fluorescence-based DNA analysis system with 16 capillaries operating in parallel, offers high-quality data and efficient sample processing for the b...
... latest 3-part differential analyzer based on the ... the CELL-DYN line. Offering 18 parameters and ... CELL-DYN 1800 meets the needs to today's ... than its predecessors and fits under standard ...
Medicine Products: